X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
(Bloomberg) — Five patient advocacy groups for diseases including cancer and AIDS urged the U.S. to force Patient Protection and Affordable Care Act insurers to lower co-payments on costly drugs, saying some plans discriminate against people with serious illness.

Representatives of the groups, which acknowledged receiving funding from pharmaceutical companies, spoke today at an event organized by the industry’s Washington-based lobbyists. That group released a study showing that 60 percent of mid-level plans on the new health exchanges placed multiple sclerosis and cancer drugs on tiers with the highest level of co-payments, in many cases requiring 30 percent of the price or more.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.